Zhou Z - Search Results

1

HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis.

Hu L, Zhou Z, Deng L, Ren Q, Cai Z, Wang B, Li Z, Wang G. Hu L, et al. Among authors: zhou z. J Pharm Pharmacol. 2020 Nov;72(11):1564-1573. doi: 10.1111/jphp.13342. Epub 2020 Jul 31. J Pharm Pharmacol. 2020. PMID: 32734608

2

Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.

Li Z, Zhou Z, Deng F, Li Y, Zhang D, Zhang L. Li Z, et al. Among authors: zhou z. Eur J Med Chem. 2018 Nov 5;159:267-276. doi: 10.1016/j.ejmech.2018.09.071. Epub 2018 Oct 1. Eur J Med Chem. 2018. PMID: 30296685

3

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.

Li Z, Chen Y, Zhou Z, Deng L, Xu Y, Hu L, Liu B, Zhang L. Li Z, et al. Among authors: zhou z. Eur J Med Chem. 2019 Feb 15;164:352-365. doi: 10.1016/j.ejmech.2018.12.069. Epub 2018 Dec 27. Eur J Med Chem. 2019. PMID: 30605833

4

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.

Li Z, Ren Q, Wang X, Zhou Z, Hu L, Deng L, Guan L, Qiu Q. Li Z, et al. Among authors: zhou z. Bioorg Chem. 2019 Nov;92:103209. doi: 10.1016/j.bioorg.2019.103209. Epub 2019 Aug 16. Bioorg Chem. 2019. PMID: 31487621

5

Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.

Li Z, Hu L, Wang X, Zhou Z, Deng L, Xu Y, Zhang L. Li Z, et al. Among authors: zhou z. Bioorg Chem. 2019 Nov;92:103254. doi: 10.1016/j.bioorg.2019.103254. Epub 2019 Sep 6. Bioorg Chem. 2019. PMID: 31518760

6

Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.

Li Z, Zhou Z, Zhang L. Li Z, et al. Among authors: zhou z. Expert Opin Ther Pat. 2020 Jan;30(1):27-38. doi: 10.1080/13543776.2020.1698546. Epub 2019 Dec 2. Expert Opin Ther Pat. 2020. PMID: 31771391 Review.

7

HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.

Chen Y, Ren Q, Zhou Z, Deng L, Hu L, Zhang L, Li Z. Chen Y, et al. Among authors: zhou z. Br J Pharmacol. 2020 May;177(10):2286-2302. doi: 10.1111/bph.14980. Epub 2020 Feb 8. Br J Pharmacol. 2020. PMID: 31971610 Free PMC article.

8

A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.

Li Z, Liu C, Zhou Z, Hu L, Deng L, Ren Q, Qian H. Li Z, et al. Among authors: zhou z. Pharmacol Res. 2020 Mar;153:104679. doi: 10.1016/j.phrs.2020.104679. Epub 2020 Jan 31. Pharmacol Res. 2020. PMID: 32014571

9

Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.

Li Z, Xu Y, Cai Z, Wang X, Ren Q, Zhou Z, Xie R. Li Z, et al. Among authors: zhou z. Bioorg Chem. 2020 Jun;99:103803. doi: 10.1016/j.bioorg.2020.103803. Epub 2020 Mar 31. Bioorg Chem. 2020. PMID: 32251945

10

Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.

Ren Q, Deng L, Zhou Z, Wang X, Hu L, Xie R, Li Z. Ren Q, et al. Among authors: zhou z. Bioorg Chem. 2020 Aug;101:103963. doi: 10.1016/j.bioorg.2020.103963. Epub 2020 May 25. Bioorg Chem. 2020. PMID: 32480174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32,852 results

Search Page

Filters